BlackRock Fund Advisors’s Avalo Therapeutics AVTX Stock Holding History

BlackRock Fund Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2K	Buy	+1	New	+$9.12K	﹤0.01%	4144
2016 Q3	–	Hold	0	–	–	–	4026
2016 Q2	–	Hold	0	–	–	–	4161

Other funds holding AVTX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TWA

TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

BlackRock Fund Advisors's AVTX Position: Q4 2016 in Review

BlackRock Fund Advisors opened a new position in Avalo Therapeutics (AVTX) in Q4 2016: 1 share worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #4144 among its holdings.

8 funds tracked by Wall St. Rank hold AVTX as of Q4 2016.

BlackRock Fund Advisors held 1 share of Avalo Therapeutics worth $2K as of Q4 2016.
Avalo Therapeutics was a new BlackRock Fund Advisors position in Q4 2016.
Avalo Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4144 holding.
8 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.